Avinger Inc., of Redwood City, Calif., reported the first patient enrollment in the IMAGE-BTK trial of its Pantheris SV image-guided atherectomy system. The postmarket study will assess safety and efficacy endpoints for Pantheris SV in the treatment of below-the-knee peripheral artery lesions.
Mississauga, Ontario-based Baylis Medical Company Inc. said a study shows that its Sureflex Steerable Guiding Sheath results in greater contact force stability for radiofrequency ablations in pulmonary vein isolations.
Salt Lake City-based Co-Diagnostics Inc. said it has designed a PCR screening test for the new coronavirus, 2019-nCOV, for use on its Coprimer platform. The test is based on World Health Organization and U.S. Centers for Disease Control and Prevention guidelines.
New Heritage Capital, a Boston-based private equity firm, reported that it has completed its sale of Northfield, N.H.-based Eptam Precision Solutions to Frazier Healthcare Partners, of Seattle. Terms of the deal were not disclosed.
Myriad Genetics Inc., of Salt Lake City, said it has filed a supplementary PMA with the U.S. FDA for its Mychoice CDx to help predict outcomes of women with first-line platinum responsive advanced ovarian cancer treated with London-based Glaxosmithkline plc’s Zejula (niraparib), a PARP inhibitor. The submission is based on positive results from the phase III PRIMA study of Zejula.
Montreal-based Investissements Novacap Inc. reported an agreement to sell a majority stake in Intelerad Medical Systems Inc., of Montreal, to London-based HG Capital. The deal is expected to close in the first quarter of 2020. Financial terms were not disclosed.
Oncimmune Holdings plc, of Nottingham, U.K., said it has joined a consortium of liver cancer companies, academics and nonprofits to research early detection of liver cancer and develop more sensitive tests. The program’s chief investigator, Ellie Barnes, received €2.5 million (US$2.8 million) from Cancer Research UK pursue the work.
Santa Rosa, Calif.-based Visquate Inc. said Fresenius Medical Care North America, of Waltham, Mass., has expanded a pilot program into a system-wide deployment of its Denials Management Analytics and Denial Flo revenue cycle management systems.